Reducing the mortality rate of hepatitis and liver cancer in Japan
暂无分享,去创建一个
[1] K. Chayama,et al. Randomized comparison of daclatasvir + asunaprevir versus telaprevir + peginterferon/ribavirin in Japanese hepatitis C virus patients , 2015, Journal of gastroenterology and hepatology.
[2] K. Chayama,et al. Randomized phase 3 trial of ombitasvir/paritaprevir/ritonavir for hepatitis C virus genotype 1b–infected Japanese patients with or without cirrhosis , 2015, Hepatology.
[3] T. Ide,et al. Sofosbuvir plus ribavirin in Japanese patients with chronic genotype 2 HCV infection: an open‐label, phase 3 trial , 2014, Journal of viral hepatitis.
[4] Y. Eguchi,et al. Current management practices for HBs antigen or anti-HCV antibody positive individuals in non-hepatology departments at a university hospital , 2013 .